论文部分内容阅读
测定９８例急性白血病（ＡＬ）患者血清可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）水平，各型ＡＬ患者ｓＩＬ－２Ｒ均明显升高，且ＡＬＬ＞Ｍ５＞Ｍ２＞Ｍ３．ｓＩＬ－２Ｒ水平与骨髓中原始细胞数、外周血白细胞数、外周成熟淋巴细胞绝对值无关。动态观察发现化疗后不能获得完全经历（ＣＲ）患者治疗前ｓＩＬ－２Ｒ明显高于获得ＣＲ患者。各型ＡＬ患者化疗ＣＲ后，ｓＩＬ－２Ｒ水平较治疗前均明显下降，除急性淋巴细胞白血病外，Ｍ２、Ｍ３、Ｍ５患者ｓＩＬ－２Ｒ均下降到正常人水平．结果表明，ＡＬ患者血清ｓＩＬ－２Ｒ水平测定，有助于对白血病的治疗及预后判断。
Serum soluble interleukin 2 receptor (sIL-2R) levels were measured in 98 patients with acute leukemia (AL). The levels of sIL-2R in all AL patients were significantly increased, and ALL> M5> M2> M3. The level of sIL-2R was not related to the number of primitive cells in the bone marrow, the number of peripheral white blood cells and the absolute value of peripheral mature lymphocytes. Dynamic observation found that patients who did not receive complete response (CR) after chemotherapy had significantly higher sIL-2R than those who received CR before treatment. The levels of sIL-2R in all AL patients after chemotherapy were significantly lower than those before treatment. The levels of sIL-2R in M2, M3 and M5 patients were all decreased to normal except acute lymphoblastic leukemia. The results show that the determination of serum sIL-2R levels in patients with AL, contribute to the treatment of leukemia and prognosis.